2.jpeg
SERVICE INTRODUCTION

When evaluating in-licensing opportunities, it is critical to include the payer perspective.
 

This helps ensure a realistic estimate of pricing and potential market size.

 

Likewise, gathering payers’ input on potential out-licensing opportunities can accelerate and enhance discussions with prospective partners.  RJW&partners provides expert support in both areas.

Evaluating New Opportunities

CASE STUDY
Assessing a European in-licensing opportunity in chemotherapy-induced diarrhoea

Our mid-sized pharma client was considering in-licensing a new product for chemotherapy-induced diarrhoea.

They sought to challenge the vendor’s assessment of the product’s commercial potential in Europe.

READ THE CASE STUDY HERE
WHERE WE FIT IN
 
NAVIGATING COMPLEX ISSUES
 
HOW WE STAND OUT
Asset 8.png

Companies often have a very limited time to assess a new in-licensing opportunity.

Identifying and thinking through the relevant issues quickly, yet thoroughly, is essential.
 

It is important to think about opportunity costs, too. Avoiding expensive mistakes is important, yet no one wants to miss a valuable opportunity that might otherwise be snapped up by a competitor.

We can quickly get “inside the payer’s head”. Our team includes experienced former payers, and we have experience across virtually every therapy area. This gives us an unrivalled understanding of the payer’s perspective on almost any product.

 

We can assess how price-sensitive decision-makers would consider a new opportunity – including informed views on a likely reimbursed price level. And we’ll identify any significant access hurdles.

Evaluating new opportunities.

Fully, and fast

CASE STUDY

International price referencing and launch sequence analysis across 120 countries

Planning a global product launch across 120 markets is complicated. Reference pricing rules in many countries adds to that complexity.

Our client, the Senior Director of Global Marketing at a mid-sized pharma, faced just this challenge with a new product for seasonal allergic rhinitis.

We helped develop an optimal launch sequence plan which took advantage of higher-priced nations, while minimising the potential downward price influence lower-priced markets.

READ THE CASE STUDY HERE